Company research
Design Therapeutics, Inc.
CIK 1807120Updated Nov 6, 2026
SecurityDSGN · NASDAQ · equity
DSGN price & chart
Loading TradingView…
NASDAQ:DSGN on TradingView ↗About the company
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
In the news
Recent filings
S-3 filing
424B5 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding Design Therapeutics, Inc.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 211,770,000Source | 261,629,000Source | 215,129,000Source | 222,886,000Source | 269,582,000Source | 230,442,000Source | 237,475,000Source | 278,793,000Source | 226,203,000Source | 252,093,000Source | 289,643,000Source | 341,137,000Source |
| Property, Plant and Equipment, NetUSD | 1,104,000Source | 1,559,000Source | 694,000Source | 1,258,000Source | 1,728,000Source | 824,000Source | 1,377,000Source | 1,718,000Source | 981,000Source | 1,410,000Source | 1,691,000Source | 1,947,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,088,000Source | 30,328,000Source | 12,907,000Source | 19,703,000Source | 45,699,000Source | 12,770,000Source | 13,667,000Source | 29,397,000Source | 16,856,000Source | 22,563,000Source | 21,200,000Source | 26,500,000Source |
| Assets, CurrentUSD | 209,029,000Source | 257,242,000Source | 212,013,000Source | 219,794,000Source | 264,842,000Source | 227,049,000Source | 233,644,000Source | 273,886,000Source | 223,784,000Source | 248,040,000Source | 284,584,000Source | 335,119,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,059,000Source | 3,168,000Source | 4,617,000Source | 3,518,000Source | 3,826,000Source | 4,226,000Source | 3,970,000Source | 3,200,000Source | 3,939,000Source | 2,563,000Source | 2,786,000Source | 4,732,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,637,000Source | 2,401,000Source | 2,422,000Source | 1,834,000Source | 2,583,000Source | 2,569,000Source | 2,027,000Source | 2,762,000Source | 1,438,000Source | 2,216,000Source | 2,938,000Source | 3,612,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 12,050,000Source | 9,176,000Source | 13,271,000Source | 9,849,000Source | 8,340,000Source | 12,388,000Source | 9,556,000Source | 9,236,000Source | 13,700,000Source | 9,996,000Source | 11,956,000Source | 13,827,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | -281,009,000Source | -213,563,000Source | -334,807,000Source | -264,012,000Source | -200,524,000Source | -314,642,000Source | -244,929,000Source | -188,731,000Source | -297,006,000Source | -227,214,000Source | -177,626,000Source | -110,764,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 358,000Source | 914,000Source | -771,000Source | 305,000Source | -217,000Source | -268,000Source | 450,000Source | -167,000Source | 403,000Source | 475,000Source | 62,000Source | -3,356,000Source |
| Stockholders' Equity Attributable to ParentUSD | 199,720,000Source | 252,453,000Source | 201,858,000Source | 213,037,000Source | 261,242,000Source | 218,054,000Source | 227,919,000Source | 269,557,000Source | 212,503,000Source | 242,097,000Source | 277,687,000Source | 327,310,000Source |
| Additional Paid in Capital, Common StockUSD | 480,365,000Source | 465,096,000Source | 537,430,000Source | 476,738,000Source | 461,977,000Source | 532,958,000Source | 472,392,000Source | 458,449,000Source | 509,100,000Source | 468,830,000Source | 455,245,000Source | 441,424,000Source |
| Liabilities and EquityUSD | 211,770,000Source | 261,629,000Source | 215,129,000Source | 222,886,000Source | 269,582,000Source | 230,442,000Source | 237,475,000Source | 278,793,000Source | 226,203,000Source | 252,093,000Source | 289,643,000Source | 341,137,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,173,000Source | 7,432,000Source | 11,240,000Source | 8,747,000Source | 6,394,000Source | 10,190,000Source | 8,236,000Source | 7,094,000Source | 13,055,000Source | 8,462,000Source | 9,622,000Source | 10,776,000Source |
| Operating Lease, Liability, CurrentUSD | 866,000Source | 778,000Source | 631,000Source | 844,000Source | 757,000Source | 536,000Source | 821,000Source | 736,000Source | 890,000Source | 800,000Source | 716,000Source | 640,000Source |
| Accounts Payable, CurrentUSD | 1,913,000Source | 1,470,000Source | 3,141,000Source | 1,013,000Source | 1,297,000Source | 2,276,000Source | 3,180,000Source | 1,372,000Source | 2,312,000Source | 2,186,000Source | 1,940,000Source | 3,025,000Source |
| Operating Lease, Liability, NoncurrentUSD | 877,000Source | 1,744,000Source | 2,031,000Source | 1,102,000Source | 1,946,000Source | 2,198,000Source | 1,320,000Source | 2,142,000Source | 645,000Source | 1,534,000Source | 2,334,000Source | 3,051,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,260,000Source | 5,962,000Source | 8,099,000Source | 7,734,000Source | 5,097,000Source | 7,914,000Source | 5,056,000Source | 5,722,000Source | 10,743,000Source | 6,276,000Source | 7,682,000Source | 7,751,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 206,000,000Source | 254,100,000Source | 207,400,000Source | 216,300,000Source | 261,000,000Source | 222,800,000Source | 229,700,000Source | 270,700,000Source | 219,800,000Source | 245,500,000Source | 281,800,000Source | 330,400,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 546,000Source | 836,000Source | 975,000Source | 1,168,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -17,636,000Source | -17,715,000Source | -69,792,000Source | -49,588,000Source | -66,862,000Source | -63,308,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,924,000Source | 3,539,000Source | 14,549,000Source | 13,072,000Source | 13,088,000Source | 10,925,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -16,431,000Source | -16,789,000Source | -54,358,000Source | -43,105,000Source | -58,560,000Source | -51,317,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -7,589,000Source | 7,870,000Source | 22,913,000Source | 43,955,000Source | 52,536,000Source | -220,987,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 72,000Source | 193,000Source | 340,000Source | 256,000Source | 918,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 19,934,000Source | 23,000Source | 25,738,000Source | 513,000Source | 724,000Source | 235,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,086,000Source | -8,896,000Source | -5,707,000Source | 1,363,000Source | -5,300,000Source | -272,069,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 15,088,000Source | 30,328,000Source | 12,907,000Source | 19,703,000Source | 12,770,000Source | 13,667,000Source | 16,856,000Source | 22,563,000Source | 21,200,000Source | 26,500,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,590,000Source | 3,118,000Source | 3,867,000Source | 3,985,000Source | 3,924,000Source | 3,539,000Source | 14,549,000Source | 13,072,000Source | 13,088,000Source | 10,925,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 206,000,000Source | 254,100,000Source | 207,400,000Source | 216,300,000Source | 222,800,000Source | 229,700,000Source | 219,800,000Source | 245,500,000Source | 281,800,000Source | 330,400,000Source |
| DepreciationUSD | — | — | — | — | — | — | 157,000Source | 159,000Source | 622,000Source | 596,000Source | 537,000Source | 406,000Source |
| General and Administrative ExpenseUSD | — | — | 4,722,000Source | 4,370,000Source | 5,789,000Source | 5,831,000Source | 5,327,000Source | 5,041,000Source | 20,338,000Source | 18,033,000Source | 21,127,000Source | 18,980,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 2,314,000Source | 3,207,000Source | 2,012,000Source | 2,486,000Source | 2,070,000Source | 2,703,000Source | 9,675,000Source | 12,795,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,997,000Source | -13,039,000Source | -20,165,000Source | -19,083,000Source | -17,636,000Source | -17,715,000Source | -69,792,000Source | -49,588,000Source | -66,862,000Source | -63,308,000Source |
| Operating ExpensesUSD | — | — | 19,311,000Source | 16,246,000Source | 22,177,000Source | 21,569,000Source | 19,706,000Source | 20,418,000Source | 79,467,000Source | 62,383,000Source | 78,190,000Source | 67,593,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 3,207,000Source | — | — | — | — | — | — | 11,328,000Source | 4,285,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 52,589,000Source | 86,548,000Source | 291,779,000Source | 230,175,000Source | 224,703,000Source | 312,998,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 19,907,000Source | 0Source | 24,847,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 27,000Source | 23,000Source | 242,000Source | 36,000Source | 419,000Source | 323,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Operating Income (Loss)USD | — | — | -19,311,000Source | -16,246,000Source | -22,177,000Source | -21,569,000Source | -19,706,000Source | -20,418,000Source | -79,467,000Source | -62,383,000Source | -78,190,000Source | -67,593,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 3,207,000Source | — | — | — | — | — | — | 11,328,000Source | 4,285,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,997,000Source | -13,039,000Source | -20,165,000Source | -19,083,000Source | -17,636,000Source | -17,715,000Source | -69,792,000Source | -49,588,000Source | -66,862,000Source | -63,308,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.3Source | -0.23Source | -0.32Source | -0.34Source | -0.29Source | -0.31Source | -1.22Source | -0.88Source | -1.19Source | -1.14Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.3Source | -0.23Source | -0.32Source | -0.34Source | -0.29Source | -0.31Source | -1.22Source | -0.88Source | -1.19Source | -1.14Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 56,950,999Source | 56,620,731Source | 62,505,340Source | 56,859,388Source | 61,434,457Source | 56,757,827Source | 57,330,192Source | 56,587,142Source | 55,984,670Source | 55,707,517Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 56,950,999Source | 56,620,731Source | 62,505,340Source | 56,859,388Source | 61,434,457Source | 56,757,827Source | 57,330,192Source | 56,587,142Source | 55,984,670Source | 55,707,517Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 4,722,000Source | 4,370,000Source | 5,789,000Source | 5,831,000Source | 5,327,000Source | 5,041,000Source | 20,338,000Source | 18,033,000Source | 21,127,000Source | 18,980,000Source |
| Investment Income, InterestUSD | — | — | 2,314,000Source | 3,207,000Source | 2,012,000Source | 2,486,000Source | 2,070,000Source | 2,703,000Source | 9,675,000Source | 12,795,000Source | — | — |
| Operating ExpensesUSD | — | — | 19,311,000Source | 16,246,000Source | 22,177,000Source | 21,569,000Source | 19,706,000Source | 20,418,000Source | 79,467,000Source | 62,383,000Source | 78,190,000Source | 67,593,000Source |
| Research and Development ExpenseUSD | — | — | 14,589,000Source | 11,876,000Source | 16,388,000Source | 15,738,000Source | 14,379,000Source | 15,377,000Source | 59,129,000Source | 44,350,000Source | 57,063,000Source | 48,613,000Source |
Offerings
Registration 333-299827
Filing attachments
dsgn-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway Carlsbad, Calif., November 4, 2026 - Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today repo…
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong fi…
Read attachment ↗p12177262_ex99-1.htm · SCHEDULE 13G · 2026-06-09
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2026-04-28
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution Carlsbad, Calif., April 28, 2026 - Design Th…
Read attachment ↗dsgn-ex99_1.htm · 8-K · 2026-03-09
EX-99.1 2 dsgn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution Carlsbad, Calif., March 9, 2026 - Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology compa…
Read attachment ↗